
- Oncology NEWS International Vol 18 No 3
- Volume 18
- Issue 3
Oncolytics kicks off reovirus trial
Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.
Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.
Articles in this issue
over 16 years ago
Genetics opens new window on acute myeloid leukemiaover 16 years ago
Pralatrexate: Upfront Rx strategy for T-cell lymphomaover 16 years ago
Who's Newsover 16 years ago
Functional MRI boosts early staging of cervical cancerover 16 years ago
Unseen bone lesions flare up on post-Rx NSCLC scansover 16 years ago
Exercise jumpstarts quality of life in lung caover 16 years ago
Champions strikes deal with Concordiaover 16 years ago
PET/CT picks up additional lesions not found on chest CTover 16 years ago
Targeted therapies address hard-to-treat liver tumorsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.